Compass Pathways Announces Publication of Results from Phase 2 Study of COMP360 Psilocybin for Post-Traumatic Stress Disorder

Stock Information for COMPASS Pathways Plc

Loading

Please wait while we load your information from QuoteMedia.

More Recent News About COMPASS Pathways Plc

Compass Pathways to Participate in Four Investor Conferences in September
Compass Pathways to Participate in Canaccord Genuity 45th Annual Growth Conference on August 12, 2025 in Boston, MA
Compass Pathways Announces Second Quarter 2025 Financial Results and Business Highlights
Compass Pathways Appoints Justin Gover to Board of Directors
Compass Pathways to Announce Second Quarter Financial Results on July 31, 2025
Compass Pathways to Participate in HC Wainwright @Home Series Interview on July 14th, 8:00am ET
Global Neuro-Psychiatric Disorders & Treatment Market Projected to Reach $166 Billion by 2032
Compass Pathways Successfully Achieves Primary Endpoint in First Phase 3 Trial Evaluating COMP360 Psilocybin for Treatment-Resistant Depression

Market data content copyright © QuoteMedia. Data delayed at least 15 minutes unless otherwise indicated (view Delay Times for all exchanges). Filings and Fundamentals by Morningstar. Insiders by Morningstar (USA) and SEDI (CDN). Analyst ratings by Zacks. Terms of Use.